Aug 13, 2026 04:01PM
May 14, 2026 04:01PM
Mar 19, 2026 04:01PM
Nov 13, 2025 04:01PM
Oct 18, 2025 08:00AM
Aug 20, 2025 04:05PM
Jun 2, 2025 04:01PM NuCana Reports First Quarter 2025 Financial Results and Provides Business Update
Mar 20, 2025 04:01PM
Nov 25, 2024 07:00AM
Feb 28, 2022 04:01PM
Feb 28, 2022 04:01PM
Feb 22, 2022 04:01PM
Feb 22, 2022 04:01PM
Feb 22, 2022 04:01PM NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study
Nov 18, 2021 04:01PM
Nov 18, 2021 04:01PM
Nov 10, 2021 08:00AM
Nov 10, 2021 08:00AM
Nov 1, 2021 04:39PM
Nov 1, 2021 04:01PM
Nov 1, 2021 04:01PM NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors
Sep 29, 2021 08:01AM
Sep 29, 2021 08:00AM
Sep 29, 2021 08:00AM
Sep 16, 2021 08:00AM
Sep 16, 2021 08:00AM
Sep 15, 2021 08:00AM
Sep 15, 2021 08:00AM NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study
Aug 19, 2021 04:01PM
Aug 19, 2021 04:01PM
Dec 21, 2020 04:11PM
Dec 21, 2020 04:01PM
Dec 1, 2020 09:25AM
Nov 30, 2020 05:41PM
Nov 30, 2020 04:04PM NuCana (NCNA) Announces Final Data from Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist
Nov 30, 2020 04:01PM
Nov 30, 2020 04:01PM
Sep 17, 2020 09:29AM
Mar 4, 2020 07:06AM
Mar 4, 2020 07:00AM
Mar 4, 2020 07:00AM
Jan 27, 2020 07:09AM NuCana (NCNA) Reports First Patient Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for First-Line Treatment of Patients with Biliary Tract Cancer
Jan 27, 2020 07:00AM
Jan 27, 2020 07:00AM
Nov 13, 2019 04:01PM
Nov 13, 2019 04:01PM
Oct 25, 2019 07:08AM
Oct 25, 2019 07:00AM
Oct 25, 2019 07:00AM NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer
Aug 21, 2019 04:01PM

328,702 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All